S. Auerbach

发表

Erectile response with vardenafil in sildenafil nonresponders: a multicentre, double‐blind, 12‐week, flexible‐dose, placebo‐controlled erectile dysfunction clinical trial

D. Hatzichristou, C. Carson, H. J. Wilkins, 2004, BJU international.

EFFICACY AND SAFETY OF APOMORPHINE SL VS PLACEBO FOR MALE ERECTILE DYSFUNCTION (MED)

S. Auerbach, H. Padma-nathan, R. Lewis, 1999 .

Safety and tolerability of the β3‐adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12‐week randomised Phase III trials and of a 1‐year randomised Phase III trial

V. Nitti, S. Herschorn, P. Radziszewski, 2014, International journal of clinical practice.

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.

J. Waldstreicher, A. Matsumoto, J. Rajfer, 2003, Urology.

Vardenafil demonstrates first-dose success and reliability of penetration and maintenance of erection in men with erectile dysfunction - RELY-II.

F. Montorsi, L. Valiquette, S. Auerbach, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.

C. Roehrborn, K. McVary, G. Sides, 2007, The Journal of urology.

Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial.

W. Shen, C. Beasley, S. Auerbach, 2005, Journal of andrology.

First‐dose success with vardenafil in men with erectile dysfunction and associated comorbidities: RELY‐I

F. Montorsi, L. Valiquette, S. Auerbach, 2006, International journal of clinical practice.

Erectile response to vardenafil in men with a history of nonresponse to sildenafil: a time-from-dosing descriptive analysis.

D. Hatzichristou, C. Carson, H. J. Wilkins, 2005, Clinical therapeutics.

Vardenafil is effective and well‐tolerated for treating erectile dysfunction in a broad population of men, irrespective of age

F. Montorsi, I. Eardley, F. Giuliano, 2005, BJU international.

Tadalafil Relieves Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

C. Roehrborn, K. McVary, G. Sides, 2007 .

Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia.

W. White, A. Mazzu, P. Sundaresan, 2004, Urology.

Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial.

J. Susset, N. Zinner, M. Gittelman, 2004, The Journal of urology.

The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.

L. Cardozo, V. Nitti, M. B. Blauwet, 2014, Age and ageing.

Results of a randomized phase III trial of mirabegron in patients with overactive bladder.

V. Nitti, S. Herschorn, N. Martin, 2013, The Journal of urology.

Recurrent polypoid hamartoma and epithelial cell nests in the ureter and renal pelvis of an adolescent.

S. Auerbach, J. Mcdonald, H. Lewis, 1966, The Journal of urology.

Long-term safety and effectiveness of sildenafil citrate in men with erectile dysfunction

S. Auerbach, R. Feldman, J. Mcmurray, 2007, Therapeutics and clinical risk management.

THE EFFICACY AND SAFETY OF TADALAFIL ADMINISTERED ONCE A DAY FOR LOWER URINARY TRACT SYMPTOMS (LUTS) IN MEN WITH BENIGN PROSTATIC HYPERPLASIA (BPH)

C. Roehrborn, G. Sides, J. Kaminetsky, 2006 .

Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment

C. Roehrborn, L. Viktrup, J. Kaminetsky, 2010, BJU international.

Axial penile rigidity as primary efficacy outcome during multi-institutional in-office dose titration clinical trials with alprostadil alfadex in patients with erectile dysfunction

I. Goldstein, J. Rajfer, S. Auerbach, 2000, International Journal of Impotence Research.

A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia.

H. Lepor, P. Narayan, M. Soloway, 1992, The Journal of urology.

OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.

C. Fowler, D. Hale, J. Kowalski, 2012, European urology.

Vardenafil restores erectile function to normal range in men with erectile dysfunction.

F. Montorsi, I. Eardley, F. Giuliano, 2007, The journal of sexual medicine.

Long-term safety and efficacy of oral phentolamine mesylate (Vasomax®) in men with mild to moderate erectile dysfunction

I. Goldstein, P. Lammers, I. Klimberg, 2002, International Journal of Impotence Research.

Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis.

F. Montorsi, S. Auerbach, M. Collins, 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.

C. Roehrborn, R. Secrest, A. Esler, 2012, The journal of sexual medicine.

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

L K Lloyd, J. Oesterling, C. Roehrborn, 1996, Urology.

A randomized, double-blind, multicenter comparison of gatifloxacin versus ciprofloxacin in the treatment of complicated urinary tract infection and pyelonephritis.

T. Marbury, C. Cox, Joanna Y Yang, 2002, Clinical therapeutics.

885 THE EFFICACY AND SAFETY OF MIRABEGRON IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME – RESULTS FROM A NORTH-AMERICAN PHASE III TRIAL

V. Nitti, S. Herschorn, N. Martin, 2011 .

1959 MIRABEGRON IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME - RESULTS FROM A NORTH-AMERICAN STUDY

V. Nitti, S. Herschorn, M. B. Blauwet, 2011 .

1958 THE SELECTIVE β3-ADRENORECEPTOR AGONIST MIRABEGRON IS EFFECTIVE AND WELL TOLERATED IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME

V. Nitti, S. Herschorn, N. Martin, 2011 .

Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment

C. Roehrborn, L. Viktrup, J. Kaminetsky, 2010, BJU international.